[BMY] Bristol-Myers Squibb Company


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 128.21 B

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 59.6 Change: 0.82 (1.4%)
Ext. hours: Change: 0 (0%)

chart BMY

Refresh chart

Strongest Trends Summary For BMY

BMY is in the long-term down -30% below S&P in 1 year and up 231% in 21 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company?s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding1.67 B EPS2.51 EPS Growth - 4 Quarters-704.03% EPS Growth - Q/Q-233.04%
EPS Growth - Y/Y-255.12% Sales Growth - 4 Quarters 6.17% Sales Growth - Q/Q3.02% P/E21.7
P/E To EPS Growth0.28 P/S7.83 P/BV8.48 Price/Cash Per Share23.41
Price/Free Cash Flow48.9 ROA5.6% ROE11.84% ROI7.56%
Current Ratio1.76 Quick Ratio1.58 Long Term Debt/Equity1.18 Debt Ratio0.49
Gross Margin76.6% Operating Margin14.94% Net Profit Margin10.93% Dividend Payout Ratio-136.15%
Dividend Yield-1.9%
Fundamental Data
Cash From Financing Activities-1.57 B Cash From Investing Activities-526 M Cash From Operating Activities697 M Gross Profit3.18 B
Net Profit-130 M Operating Profit45 M Total Assets31.95 B Total Current Assets13.06 B
Total Current Liabilities7.44 B Total Debt7.37 B Total Liabilities16.83 B Total Revenue4.16 B
Technical Data
High 52 week68.98 Low 52 week44.62 Last close46.85 Last change-0.57%
RSI53.8 Average true range0.98 Beta0.67 Volume5.04 M
Simple moving average 20 days0.65% Simple moving average 50 days-0.72% Simple moving average 200 days-10.35%
Performance Data
Performance Week-0.34% Performance Month2.29% Performance Quart-8.53% Performance Half-10.11%
Performance Year-25.2% Performance Year-to-date-9.05% Volatility daily1.34% Volatility weekly3%
Volatility monthly6.16% Volatility yearly21.32% Relative Volume180.93% Average Volume18.66 M
New High New Low


2019-06-21 10:01:02 | 3 Big Biotechs Hold Growth Potential in Second Half of 2019

2019-06-21 09:07:01 | Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

2019-06-21 08:00:00 | Where Will bluebird bio Be in 1 Year?

2019-06-20 09:05:00 | What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?

2019-06-19 17:45:00 | This would be the worst-case scenario for health companies, according to UBS

2019-06-19 11:04:03 | The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands

2019-06-19 09:06:01 | Big Drugmakers That May Tread the M&A Path After Pfizer

2019-06-19 09:00:01 | Bristol-Myers BMY Upgraded to Buy: What Does It Mean for the Stock?

2019-06-18 17:45:09 | Bristol-Myers Squibb BMY Stock Sinks As Market Gains: What You Should Know

2019-06-18 14:11:37 | 2019 Business of Pride honorees: Bristol-Myers Squibb

2019-06-18 13:00:05 | Top Analyst Reports for Broadcom, Amgen & NVIDIA

2019-06-18 09:51:01 | Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio

2019-06-17 09:35:04 | Pfizer Expands in Cancer With $10.6 Billion Deal for Array

2019-06-16 09:00:00 | Is It Too Late to Buy Celgene Stock?

2019-06-14 13:52:24 | Should Bristol-Myers Squibb Company NYSE:BMY Be Part Of Your Dividend Portfolio?

2019-06-14 12:06:04 | 3 Big Pharma Stocks to Buy Right Now

2019-06-14 08:29:12 | Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

2019-06-14 06:59:00 | Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti elotuzumab Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma RRMM

2019-06-13 17:40:09 | Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris

2019-06-13 16:38:00 | Bristol-Myers Squibb Announces Dividend

2019-06-13 16:30:00 | New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® abatacept or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients

2019-06-13 09:19:00 | Price target on Bristol-Myers stock cut to $51 at UBS

2019-06-12 18:33:10 | Roche's Rituxan Gets Priority Review for Blood Disorder

2019-06-12 18:21:10 | Novartis Reports Data on Cosentyx for Psoriatic Arthritis

2019-06-12 17:45:09 | Bristol-Myers Squibb BMY Gains As Market Dips: What You Should Know

2019-06-12 10:19:02 | Zacks.com featured highlights include: CDW, Bristol-Myers, Celgene, PepsiCo and Northrop

2019-06-12 09:15:01 | Bristol-Myers Squibb BMY is a Top Dividend Stock Right Now: Should You Buy?

2019-06-12 08:28:12 | Boost Your Portfolio's Health With These 3 Big Drug Stocks

2019-06-11 18:16:10 | Insys Down on Bankruptcy News Amid Increasing Legal Expenses

2019-06-11 09:14:11 | FDA Greenlights Merck's Blockbuster Drug Keytruda For First-Line Treatment Of Head, Neck Cancer

2019-06-11 08:53:12 | Merck MRK to Buy Private Biotech Tilos for Up to $773M

2019-06-11 08:34:12 | Top 5 ROE Stocks to Buy as US-Mexico Trade Concerns Abate

2019-06-11 08:00:32 | See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

2019-06-10 12:34:04 | Sanofi SNY in Focus: Stock Moves 5.5% Higher

2019-06-10 09:57:01 | The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca

2019-06-10 08:00:11 | See what the IHS Markit Score report has to say about Bristol-Myers Squibb Co.

2019-06-07 13:06:26 | 2 Dividend Stocks to Buy That Are Better Than 3M Stock

2019-06-07 12:05:14 | Seth Klarman's Favorite Biotech Positions

2019-06-07 10:21:02 | Pharma Stock Roundup: ASCO Update, FDA Nod for LLY's Emgality for Cluster Headache

2019-06-07 09:09:01 | Novartis Appoints New Pharma Unit Head, Gives Other Updates

2019-06-06 19:17:48 | Management Changes Intended to Boost Bristol-Myers Squibb After Celgene Deal

2019-06-06 17:45:09 | Bristol-Myers Squibb BMY Stock Sinks As Market Gains: What You Should Know

2019-06-06 16:56:08 | Celgene & Acceleron's BLA for Luspatercept Accepted by FDA

2019-06-06 16:41:08 | Mallinckrodt Down After Agreement with DOJ for Litigation

2019-06-06 15:13:05 | 5 Healthcare Stocks to Pick Up From the Wreckage

2019-06-06 13:55:00 | Top 5 Stocks in the Fight Against Cancer

2019-06-06 09:09:01 | Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

2019-06-06 09:00:15 | A Look at Bristol-Myers Squibb’s Near-Term Product Launches

2019-06-06 06:59:00 | Bristol-Myers Squibb to Announce Results for Second Quarter 2019 on July 25, 2019

2019-06-05 16:30:04 | The Celgene Merger Looks Secure — So Why Is Bristol Under Pressure?